Pharmacologic management of convulsive status epilepticus in childhood

Area of Science:

• Pediatric Neurology
• Emergency Medicine

Background:

• Convulsive status epilepticus (CSE) affects 20-50/100,000 children annually, posing a significant medical emergency.
• Seizures lasting over 5 minutes require immediate intervention as they rarely resolve spontaneously.
• Delayed treatment of CSE drastically increases mortality and morbidity, particularly after 60 minutes.

Purpose of the Study:

• To review current treatment strategies for pediatric convulsive status epilepticus.
• To highlight the importance of timely intervention and effective drug choices.
• To identify areas for future research and protocol development.

Main Methods:

• Literature review of current guidelines and studies on pediatric CSE management.
• Analysis of first-, second-, and third-line treatment options.
• Emphasis on the role of electroencephalogram (EEG) monitoring.

Main Results:

• Benzodiazepines are the first-line treatment, with buccal midazolam showing improved efficacy and ease of administration over rectal diazepam.
• Intravenous phenytoin/fosphenytoin and phenobarbital are recommended second-line treatments.
• Refractory cases may require barbiturates or midazolam as intravenous anesthetics, with EEG monitoring crucial for assessing response.

Conclusions:

• Optimizing treatment for pediatric CSE necessitates individualized protocols and pathways.
• Further randomized clinical trials are essential to evaluate novel treatment protocols for improved efficacy, safety, and neuroprotection.
• The goal is to minimize neuronal injury and reduce the risk of long-term neurological morbidity.